The stock of AbCellera Biologics Inc (ABCL) has seen a 6.11% increase in the past week, with a 10.32% gain in the past month, and a -10.32% decrease in the past quarter. The volatility ratio for the week is 5.26%, and the volatility levels for the past 30 days are at 4.61% for ABCL. The simple moving average for the last 20 days is 6.47% for ABCL’s stock, with a simple moving average of -25.09% for the last 200 days.
Is It Worth Investing in AbCellera Biologics Inc (NASDAQ: ABCL) Right Now?
The stock has a 36-month beta value of 0.38. Opinions on the stock are mixed, with 7 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ABCL is 206.59M, and at present, short sellers hold a 8.26% of that float. On October 24, 2024, the average trading volume of ABCL was 1.81M shares.
ABCL) stock’s latest price update
AbCellera Biologics Inc (NASDAQ: ABCL) has experienced a decline in its stock price by -2.11 compared to its previous closing price of 2.84. However, the company has seen a gain of 6.11% in its stock price over the last five trading days. businesswire.com reported 2024-10-22 that VANCOUVER, British Columbia–(BUSINESS WIRE)—- $ABCL–AbCellera to Present at Upcoming Investor Conferences in November 2024.
Analysts’ Opinion of ABCL
The Benchmark Company, on the other hand, stated in their research note that they expect to see ABCL reach a price target of $9. The rating they have provided for ABCL stocks is “Buy” according to the report published on February 22nd, 2024.
KeyBanc Capital Markets gave a rating of “Overweight” to ABCL, setting the target price at $6 in the report published on December 05th of the previous year.
ABCL Trading at 6.96% from the 50-Day Moving Average
After a stumble in the market that brought ABCL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.09% of loss for the given period.
Volatility was left at 4.61%, however, over the last 30 days, the volatility rate increased by 5.26%, as shares surge +13.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.12% upper at present.
During the last 5 trading sessions, ABCL rose by +6.11%, which changed the moving average for the period of 200-days by -53.43% in comparison to the 20-day moving average, which settled at $2.61. In addition, AbCellera Biologics Inc saw -51.31% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ABCL
Current profitability levels for the company are sitting at:
- -8.15 for the present operating margin
- -0.86 for the gross margin
The net margin for AbCellera Biologics Inc stands at -4.64. The total capital return value is set at -0.2. Equity return is now at value -13.30, with -10.39 for asset returns.
Based on AbCellera Biologics Inc (ABCL), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -1.26. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -16.1.
Currently, EBITDA for the company is -192.16 million with net debt to EBITDA at 0.5. When we switch over and look at the enterprise to sales, we see a ratio of 21.72. The receivables turnover for the company is 0.49for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.96.
Conclusion
To sum up, AbCellera Biologics Inc (ABCL) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
